Reuters logo
Regeneron-Sanofi throat infection drug succeeds key study
2017年10月16日 / 中午12点22分 / 1 个月前

Regeneron-Sanofi throat infection drug succeeds key study

Oct 16 (Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat patients with a rare throat infection met the main goal of a mid-stage study.

The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate to severe eosinophilic esophagitis, when compared with a placebo. (Reporting by Divya Grover in Bengaluru; Editing by Martina D‘Couto)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below